Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the ACE Inhibitors Market Evolve in Terms of Growth and Size by 2029?

The market size for ACE inhibitors has consistently expanded in the past few years. It is predicted to increase from $7.15 billion in 2024 to $7.41 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.6%. The historical growth has been driven by factors such as an increase in cardiovascular diseases, an aging population, the effectiveness and safety of the drugs, the rise in diabetes cases, and regulatory approvals and guidelines.

We can foresee robust expansion in the ACE inhibitors market in the upcoming years, as it is projected to reach “$9.42 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. The expected growth during the forecast period is primarily due to an increased worldwide prevalence of cardiovascular diseases, broadening guidelines for hypertension treatment, advancements in combined therapies, a concentrated effort on heart failure management, and improved healthcare access and awareness. The forecast period is also expected to witness trends such as a focus on kidney protection, a preference for renin-angiotensin system inhibitors, generic competition and pricing challenges, patient-oriented strategies in healthcare, along with regulatory updates and safety considerations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What factors are expected to fuel ACE Inhibitors market growth in the coming years?

The growth of the ACE inhibitors market is predicted to be propelled by the rising instances of hypertension disorders. Hypertension, a medical term for high blood pressure, is typified by increased pressure in blood vessels. Angiotensin-converting enzyme inhibitors, also referred to as ACE inhibitors, form a category of drugs used to manage and treat hypertension. These drugs help by relaxing blood vessels, thereby decreasing blood pressure, and enhancing blood flow. As per data from the World Health Organization in March 2023, around 1.28 billion adults, aged between 30 and 79, globally suffered from hypertension, with the bulk of them (two-thirds) living in lower to middle-income countries. Over the last three decades, the count of people aged 30-79 with hypertension has grown by 650 million. It’s estimated that 46% of adults with hypertension are oblivious to their condition due to the absence of a diagnosis. This surging prevalence of hypertension ailments hence, is fueling the expansion of the ACE inhibitors market.

What Are The Key Findings From The Segmentation Analysis Of The ACE Inhibitors Market?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

What Are The Leading Trends And Opportunities In The ACE Inhibitors Sector?

A prevailing trend taking shape in the ACE inhibitors market is the emphasis on product innovation. To consolidate their place in the market and outpace competition, major companies have been keen on creating novel products. A case in point is Travere Therapeutics, a biopharmaceutical entity based in the U.S., who in February 2023 received the FDA’s nod for FILSPARI (sparsentan). This is a unique non-immunosuppressive therapy intended for use in IgA nephropathy (IgAN) patients. The scope of treatments includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin-receptor blockers (ARBs)-intensive hypertension drugs. It is set apart by being the solitary non-immunosuppressive therapy ratified, and it’s a daily oral medicine tailored for grown-up IgAN patients expected to display rapid disease progression and who generally show a UPCR of less than 1.5 g/g and proteinuria.

What Are The Most Active Companies In The ACE Inhibitors Market Today?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Regional Markets Are Attracting The Most Investment In ACE Inhibitors?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model